xbrl.rienks.biz
English 
Nederlands
Français
Deutsch Koninklijke Reesink N.V.
| Address | Exchange | Stocks (-: 06:00:00) | ||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
0.00%Industry: Industrials
Sector: Industrial Suppliers
Distributors and wholesalers of diversified products and equipment primarily used in the commercial and industrial sectors. Includes builders merchants.
| Buhrmann N.V. | (BUHR) | Industrial Suppliers |
| Hagemeyer N.V. | (HGM) | Industrial Suppliers |
| Koninklijke Reesink N.V. | (REES) | Industrial Suppliers |
Full Year End: 31-12
| English | Dutch | |
| Annual Report 2006 (4.53 MB) (Deloitte) Annual Report 2005 (3.61 MB) (Deloitte) | Jaarverslag 2006 (7.26 MB) (Deloitte) Jaarverslag 2005 (1.70 MB) (Deloitte) Jaarverslag 2000 (0.51 MB) (Deloitte) Jaarverslag 1999 (2.05 MB) (Deloitte) Jaarverslag 1998 (1.15 MB) (Deloitte) |
News
| Ahold Q3 profit slides, but EPS rises - Update (20 Nov)
(RTTNews) - Thursday, the Netherlands-based supermarket operator Koninklijke Ahold N.V. (AHODF.PK, AHONY.PK) posted an 8.9% fall in third-quarter profit, reflecting higher income taxes and lower income from joint ventures, but earnings per share rose slightly on lower share count... Tibotec Presents Interim Findings for TMC435, an Investigational Genotype 1 Hepatitis C Treatment, at the AASLD Liver ... (20 Nov)Cork, Ireland, November 20 (ots/PRNewswire) - - Nearly 90 Percent of Patients Achieve Undetectable Viral Load in Phase IIa Trial Within 28 Days of Combined ..... (AFX UK Focus) 2008-11-20 11:34 Glance-STOCKS NEWS EUROP-Paypoint falls on revenue concerns (20 Nov)STOCKS NEWS Reuters Results diary Stocks on the move Real-time Equity News.. | Tibotec Presents Interim Findings for TMC435, an Investigational Genotype 1 Hepatitis C Treatment, at the AASLD Liver ... (20 Nov)
New clinical data demonstrate the safety and antiviral activity of TMC435, an investigational protease inhibitor being developed by Tibotec BVBA for the treatment of chronic hepatitis C virus infection... Ahold Earnings Q3 2008 (20 Nov)Highlights.. Medialink Reports Third Quarter 2008 Results (14 Nov)Medialink Worldwide Incorporated , a leading provider of diversified media services for professional communicators and marketers, today reported financial results for the third quarter ended September 30, 2008... |
Financial Calendar
| Yearly result | Quaterly Results | Analyst & Investor Conference |
|---|---|---|
| - | Q1 - | - |
| Q2 - | - | |
| AGM | Q3 - | - |
| - | Q4 - | - |
Annual Accounts Koninklijke Reesink N.V.
| 2005-12-31 | 2006-12-31 | CHANGE | |
|---|---|---|---|
 Balance Sheet | |||
| Figures in 1.000 x EUR | |||
| Balance Sheet (Presentation) | |||
| Assets (Presentation) | |||
| Assets, Non-Current (Presentation) | |||
| Property, Plant and Equipment, Net | 41.842 | 42.509 | 1,59% |
| Investment Property | 16.031 | 16.301 | 1,68% |
| Assets Pledged as Collateral Subject to Sale or Repledging, Non-Current | 18.720 | 18.983 | 1,40% |
| Assets, Non-Current, Total | 76.593 | 77.793 | 1,57% |
| Assets, Current (Presentation) | |||
| Inventories | 26.304 | 36.497 | 38,75% |
| Other Financial Assets, Current | 597 | 521 | -12,73% |
| Trade and Other Receivables, Net, Current | 17.726 | 20.386 | 15,01% |
| Cash and Cash Equivalents | 152 | 236 | 55,26% |
| Assets, Current, Total | 44.779 | 57.640 | 28,72% |
| Assets, Total | 121.372 | 135.433 | 11,59% |
| Equity and Liabilities (Presentation) | |||
| Equity (Presentation) | |||
| Equity Attributable to Equity Holders of Parent (Presentation) | |||
| Equity, Total | 67.157 | 73.839 | 9,95% |
| Liabilities (Presentation) | |||
| Liabilities, Non-Current (Presentation) | |||
| Interest-Bearing Borrowings, Non-Current | 3.736 | 3.736 | 0,00% |
| Post-Employment Benefit Obligation, Non-Current | 720 | 720 | 0,00% |
| Deferred Tax Liabilities | 12.926 | 11.509 | -10,96% |
| Other Liabilities, Non-Current | 3.307 | 3.467 | 4,84% |
| Liabilities, Non-Current, Total | 20.689 | 19.432 | -6,08% |
| Liabilities, Current (Presentation) | |||
| Liabilities Included in Disposal Groups Classified as Held for Sale | 16.606 | 23.389 | 40,85% |
| Current Tax Payables | 1.834 | 1.825 | -0,49% |
| Trade and Other Payables, Current | 6.023 | 6.642 | 10,28% |
| Other Liabilities, Current | 9.063 | 10.306 | 13,72% |
| Liabilities, Current, Total | 33.526 | 42.162 | 25,76% |
| Liabilities, Total | 54.215 | 61.594 | 13,61% |
| Equity and Liabilities, Total | 121.372 | 135.433 | 11,59% |
|
Income Statement |
2005 | 2006 | |
| Figures in 1.000 x EUR | |||
| Income Statement (Presentation) | |||
| Profit (Loss) from Operations (Presentation) | |||
| Gross Profit (Presentation) | |||
| Revenue, Total | 128.880 | 169.290 | 31,35% |
| Cost of Sales | 112.589 | 148.054 | 31,50% |
| Gross Profit | 16.291 | 21.236 | 30,35% |
| Other Operating Income (Presentation) | |||
| Miscellaneous Other Operating Income | 1.200 | -100,00% | |
| Other Operating Income, Total | 1.200 | -100,00% | |
| Operating Expenses (Presentation) | |||
| Marketing and Distribution Costs | 7.391 | 8.115 | 9,80% |
| Administrative Expenses | 5.772 | 5.415 | -6,19% |
| Miscellaneous Other Operating Expenses | 300 | 0,00% | |
| Operating Expenses, Total | 13.163 | 13.830 | 5,07% |
| Profit (Loss) from Operations | 4.328 | 7.406 | 71,12% |
| Profit (Loss) Before Tax (Presentation) | |||
| Finance Costs [for Non-Financial Activities] | 650 | 818 | 25,85% |
| Income (Loss) from Investments | 499 | 1.384 | 177,35% |
| Share of Profit (Loss) from Equity-Accounted Investments | 176 | -100,00% | |
| Share of Profit (Loss) from Equity-Accounted Associates | 176 | -100,00% | |
| Profit (Loss) Before Tax | 4.353 | 7.972 | 83,14% |
| Profit (Loss) After Tax from Continuing Operations (Presentation) | |||
| Income Tax Expense (Income) | 1.145 | 1.939 | 69,34% |
| Profit (Loss) After Tax from Continuing Operations | 3.208 | 6.033 | 88,06% |
| Profit (Loss) (Presentation) | |||
| Profit (Loss) Attributable to Equity Holders of Parent and Minority Interest (Presentation) | |||
| Earnings Per Share (Presentation) | |||
| Basic Earnings (Loss) Per Share | 4,71 | 8,92 | 89,38% |
|
Ratios & key-indices | |||
| Liquidity | |||
| Current Ratio | 133,56% | 136,71% | 2,30% |
| Quick Ratio / Acid Test | 55,11% | 50,15% | -9,89% |
| Working Capital | 11.253.000 | 15.478.000 | 27,30% |
| Balance ratios | |||
| Equity Ratio | 55,33% | 54,52% | -1,49% |
| Debt ratios | |||
| Debt-Asset Ratio | 44,67% | 45,48% | 1,78% |
| Debt to Equity Ratio | 80,73% | 83,42% | 3,22% |
| Profitability | |||
| Gross Profit Margin | 0,00% | 0,00% | 0,00% |
| Profit Margin | 0,00% | 0,00% | 0,00% |
| Operating Profit Margin | 3,36% | 4,37% | 23,24% |
| Rate of Return | |||
| Return on Capital Employed Ratio | 0,00% | 0,00% | 0,00% |
| Return on Fixed Assets | 5,68% | 10,25% | 44,54% |
| Return on Working Capital | 38,68% | 51,51% | 24,90% |